Atlas Bio raises $12.5M for AI model to simulate clinical trials

Swiss startup Atlas Bio emerged from stealth with $12.5 million in funding: a $10 million Seed led by Creandum and a $2.5 million pre-Seed from First Momentum Ventures and LEA Partners. The company is building a foundation AI model trained on roughly 2 million human RNA readouts to simulate drug efficacy and safety before Phase II and replace animal testing.

• Total funding reaches $12.5M, including a $10M Seed round led by Creandum
• The model is trained on about 2 million human RNA readouts
• Around 70% of drugs fail Phase II, which costs $100M+ and takes 2–3 years
• One Basel-based client has already dropped animal testing based on the simulation